Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 5 mg | $18.00 | In stock | — | |
| 10 mg | $32.00 | In stock | — |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
Sermorelin is the first 29 amino acids of human growth hormone releasing hormone, GHRH(1-29)-NH2, the shortest fragment with the full activity of the hormone. It is supplied as the acetate salt.
Identity
| Type | Synthetic peptide, 29 amino acids, acetate salt |
|---|---|
| Molecular formula | C149H246N44O42S (free base) |
| Molecular weight | 3357.9 g/mol (free base) |
| CAS number | 86168-78-7 |
| PubChem CID | 16132413 |
Sermorelin is the synthetic 29-amino-acid peptide Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2, identical to residues 1 to 29 of human GHRH, with an amidated C-terminus. Molecular formula C149H246N44O42S and molecular weight 3357.9 g/mol for the free base (PubChem CID 16132413, CAS 86168-78-7). It is supplied as the acetate salt: the acetate counterions are part of the powder but not of the peptide mass that mass spectrometry confirms. Its single sulfur atom is in methionine 27, which can oxidize to the sulfoxide, a degradation product that HPLC separates from the intact peptide; it contains no cysteine. It is supplied as a white lyophilized powder in a sealed vial.
What the published research covers
Sermorelin was developed and studied clinically as a stimulus for growth hormone release from the pituitary.
Growth hormone releasing hormone (GHRH) was first isolated not from the hypothalamus but from pancreatic tumors that had caused acromegaly. In 1982 Roger Guillemin's laboratory reported a 44-amino-acid amidated peptide from such a tumor whose synthetic copy stimulated growth hormone secretion in vitro and in vivo (Guillemin, 1982). Structure-activity work then shortened it. On cultured rat pituitary cells, the amidated fragment 1-29 kept full intrinsic activity at about half the potency of the whole peptide (Ling, 1984). That fragment, GHRH(1-29)-NH2, is sermorelin.
Sermorelin was developed clinically by Serono under the name GEREF. In a National Institute on Aging study, 10 healthy older men given sermorelin for 14 days at two levels showed increases in 24-hour growth hormone secretion and IGF-I that, at the higher level, no longer differed from those of young men (Corpas, 1992). The main pediatric study was a multicenter, open-label trial in 110 previously untreated prepubertal children with growth hormone deficiency; mean height velocity rose from 4.1 cm a year at baseline to 8.0 and 7.2 cm a year at 6 and 12 months, and bone age did not advance faster than height age (Thorner, 1996). A review of the clinical program described sermorelin as the shortest synthetic peptide with the full biological activity of GHRH, and reported that the increases in height velocity in comparison studies were smaller than with recombinant growth hormone (Prakash, 1999).
The FDA approved GEREF in 1990 as a diagnostic agent for testing the pituitary's capacity to secrete growth hormone, and in 1997 for idiopathic growth hormone deficiency in children with growth failure. EMD Serono discontinued both products in 2008, and the FDA withdrew the approvals in 2009; in 2013 the agency published its determination that they were not withdrawn from sale for reasons of safety or effectiveness. The clinical record dates from the 1980s and 1990s, the pediatric trial compared each child with their own baseline rather than with a control group, and the studies in older adults were small and short. Those approvals covered the GEREF product only.
Regulatory status
Formerly an FDA-approved prescription product, since discontinued by its manufacturer. This material is not that product and is supplied for laboratory research only.
Testing and documentation
Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strengths is sermorelin acetate offered in?
- Vials of 5 mg and 10 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is this the FDA-approved product GEREF?
- No. GEREF, the sermorelin product once approved by the FDA, was discontinued by its manufacturer in 2008, and its approvals were withdrawn in 2009. This material is a research peptide of the same sequence, supplied for laboratory research only.
- Why are the formula and weight given for the free base?
- Sermorelin is supplied as the acetate salt, and the amount of acetate can vary between batches. The free-base formula and weight describe the peptide itself, which is what mass spectrometry confirms.
- How is a batch tested?
- By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Guillemin R et al. (1982). Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. PubMed 6812220
- Ling N et al. (1984). Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor. Biochemical and Biophysical Research Communications. PubMed 6435620
- Corpas E et al. (1992). Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. PubMed 1379256
- Thorner M et al. (1996). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Journal of Clinical Endocrinology and Metabolism. PubMed 8772599
- Prakash A et al. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PubMed 18031173
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement